NCT01262638View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

PHASE2CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

August 23, 2011

Study Completion Date

August 23, 2011

Conditions
Dyslipidemia
Interventions
DRUG

ETC-1002

ETC-1002 daily for 12 weeks

DRUG

Placebo

Placebo daily for 12 weeks

Trial Locations (11)

23294

Richmond

27609

Raleigh

32216

Jacksonville

40213

Louisville

49007

Kalamazoo

52242

Iowa City

60654

Chicago

77030

Houston

85225

Chandler

94904

Greenbrae

95405

Santa Rosa

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY